Related Experiment Video
Updated: Aug 15, 2026

Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
[Place of ticlopidine in antiplatelet treatment]
Ryszard Wlazłowski1, Aleksander Goch, Jan Henryk Goch
1Oddział Kardiologiczny Szpitala Zakonu Bonifratrów Swietego Jana Bozego, Lodzi.
Abstract:
Ticlopidine is an inhibitor of platelets function in vivo. It inhibits platelets aggregation induced by ADP. Its mode of action has not been defined, but it appears that metabolites of ticlopidine are antagonists of the platelet ADP receptor. Inhibition of platelet aggregation is delayed until 24 to 48 hours after drug administration, achieving maximum after 3 to 5 days of treatment. Recovery of platelet function occurs from 4 to 14 days after discontinuation of ticlopidine. It is potent antiplatelet factor, possible to use (among other in view of low price) in secondary prevention of cardiovascular diseases as alternative drug, especially in prevention of thrombosis during coronary stent placement.. Use of ticlopidine is limited by numerous side effects forcing quite often to discontinuation of therapy. It seems, that better safety profile, and it probably larger efficiency shows different derivative of thienopiridyn--clopidogrel.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Transient Ischemic Attack l: Introduction
Anticoagulant Drugs: Low-Molecular-Weight Heparins

